Baseline levels and decrease in serum soluble intercellular adhesion molecule-1 during chemotherapy predict objective response and survival in patients who have advanced non-small-cell lung cancer

Clinical Lung Cancer

Volumn 12, Issue 2, 2011, Pages 131-137

  Qian, Qian ^a   Zhan, Ping ^b   Yu, Like ^b   Shi, Yi ^a   Cheng, Jinfei ^c   Wei, Shuzhen ^a   Wang, Qian ^a   Song, Yong ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b NANJING CHEST HOSPITAL   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Predictive factor; Prognostic factor; Soluble intercellular adhesion molecule 1; Vascular endothelial growth factor

Indexed keywords

CISPLATIN; GEMCITABINE; INTERCELLULAR ADHESION MOLECULE 1; PACLITAXEL; PEMETREXED; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

EID: 79959362453     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.03.009     Document Type: Article

References (30)

1. Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008; 83:584-94. (Pubitemid 351720831)
2. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22:330-53.
3. Martini N, Kris MG, Gralla RJ, et al. The effects of preoperative chemotherapy on the resectability of non-small cell lung carcinoma with mediastinal lymph node metastases (N2 M0). Ann Thorac Surg 1988; 45:370-9. (Pubitemid 18097323)
4. Rothlein R, Mainolfi EA, Czajkowski M, et al. A form of circulating ICAM-1 in human serum. J Immunol 1991; 147:3788-93.
5. Fonsatti E, Altomonte M, Coral S, et al. Tumour-derived interleukin 1alpha (IL-1alpha) up-regulates the release of soluble intercellular adhesion molecule-1 (sICAM-1) by endothelial cells. Br J Cancer 1997; 76:1255-61. (Pubitemid 27474964)
6. Marino M, Scuderi F, Mazzarelli P, et al. Constitutive and cytokine-induced expression ofMHCand intercellular adhesion molecule-1 (ICAM-1) on human myoblasts. J Neuroimmunol 2001; 116:94-101. (Pubitemid 32322643)
7. Gearing AJ, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993; 14:506-12. (Pubitemid 23301002)
8. Van de Stolpe A, Van der Saag PT. Intercellular adhesion molecule-1. J Mol Med 1996; 74:13-33. (Pubitemid 26035754)
9. Alexiou D, Karayiannakis AJ, Syrigos KN, et al. Serum levels of E-selectin, ICAM-1 and VCAM-1 in colorectal cancer patients: correlations with clinicopathological features, patient survival and tumour surgery. Eur J Cancer 2001; 37:2392-7. (Pubitemid 33097476)
10. Viac J, Vincent C, Palacio S, et al. Tumour necrosis factor (TNF) soluble receptors in malignant melanoma: correlation with soluble ICAM-1 levels. Eur J Cancer 1996; 32A:447-9.
11. Nakata B, Hori T, Sunami T, et al. Clinical significance of serum soluble intercellular adhesion molecule 1 in gastric cancer. Clin Cancer Res 2000; 6:1175-9. (Pubitemid 30159382)
12. Gho YS, Kleinman HK, Sosne G. Angiogenic activity of human soluble intercellular adhesion molecule-1. Cancer Res 1999; 59:5128-32. (Pubitemid 29503972)
13. Gho YS, Kim PN, Li HC, et al. Stimulation of tumor growth by human soluble intercellular adhesion molecule-1. Cancer Res 2001; 61:4253-7. (Pubitemid 32720996)
14. Osaki T, Mitsudomi T, Yoshida Y, et al. Increased levels of serum intercellular adhesion molecule-1 (ICAM-1) in patients with non-small cell lung cancer. Surg Oncol 1996; 5:107-13. (Pubitemid 26385510)
15. Grothey A, Heistermann P, Philippou S, et al. Serum levels of soluble intercellular adhesion molecule-1 (ICAM-1, CD54) in patients with non-small-cell lung cancer: correlation with histological expression of ICAM-1 and tumour stage. Br J Cancer 1998; 77:801-7. (Pubitemid 28077470)
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-16.
17. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143:29-36. (Pubitemid 12142173)
18. Dowlati A, Gray R, Sandler AB, et al. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-an Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008; 14:1407-12. (Pubitemid 351413922)
19. Leeuwenberg JF, Smeets EF, Neefjes JJ, et al. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 1992; 77:543-9. (Pubitemid 23000475)
20. Lyons PD, Benveniste EN. Cleavage of membrane-associated ICAM-1 from astrocytes: involvement of a metalloprotease. Glia 1998; 22:103-12. (Pubitemid 28084382)
21. Champagne B, Tremblay P, Cantin A, et al. Proteolytic cleavage of ICAM-1 by human neutrophil elastase. J Immunol 1998; 161:6398-405. (Pubitemid 28536017)
22. Whiteman SC, Bianco A, Knight RA, et al. Human rhinovirus selectively modulates membranous and soluble forms of its intercellular adhesion molecule-1 (ICAM-1) receptor to promote epithelial cell infectivity. J Biol Chem 2003;278:11954-61. (Pubitemid 36800169)
23. Wakatsuki T, Kimura K, Kimura F, et al. A distinct mRNA encoding a soluble form of ICAM-1 molecule expressed in human tissues. Cell Adhes Commun 1995; 3:283-92. (Pubitemid 26009600)
24. Folkman J. What is the evidence that tumors are angiogenesis dependent. J Natl Cancer Inst 1990; 82:4-6. (Pubitemid 20020880)
25. Rieckmann P, Michel U, Albrecht M, et al. Soluble forms of intercellular adhesion molecule-1 (ICAM-1) block lymphocyte attachment to cerebral endothelial cells. J Neuroimmunol 1995; 60:9-15.
26. Becker JC, Dummer R, Hartmann AA, et al. Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity. J Immunol 1991; 147: 4398-401.
27. Bossu P, Singer GG, Andres P, et al. Mature CD4-T lymphocytes from MRL/lpr mice are resistant to receptor-mediated tolerance and apoptosis. J Immunol 1993; 151:7233-9. (Pubitemid 24001098)
28. Bremnes RM, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 2006; 51:143-58. (Pubitemid 43144358)
29. Laack E, Scheffler A, Burkholder I, et al. Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC). Lung Cancer 2005; 50:51-8. (Pubitemid 41297469)
30. Dudek AZ, Mahaseth H. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Cancer Invest 2005; 23:193-200. (Pubitemid 40770736)